Last reviewed · How we verify
Partial Central Diabetes Insipidus
Approved treatments
- Lysipressin · Novartis
- L-Lysine · Advanced Accelerator Applications
- Minirin · Hormozgan University of Medical Sciences
- Ddavp · Ferring Pharms Inc
- Argipressin · Kristina Svennerholm
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Partial Central Diabetes Insipidus patent landscape — cliff calendar, originator estates, attackable patents
- Partial Central Diabetes Insipidus treatment landscape brief
- Partial Central Diabetes Insipidus treatment updates RSS
Frequently asked questions about Partial Central Diabetes Insipidus
What drugs treat Partial Central Diabetes Insipidus?
Tracked treatments include Lysipressin, L-Lysine, Minirin, Ddavp, Argipressin.
What is the treatment for Partial Central Diabetes Insipidus?
Standard treatment for Partial Central Diabetes Insipidus includes Lysipressin, L-Lysine, Minirin, Ddavp, Argipressin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Partial Central Diabetes Insipidus patent cliff · Partial Central Diabetes Insipidus CI report
- Treatment: Lysipressin · Novartis
- Treatment: L-Lysine · Advanced Accelerator Applications
- Treatment: Minirin · Hormozgan University of Medical Sciences
- Treatment: Ddavp · Ferring Pharms Inc
- Treatment: Argipressin · Kristina Svennerholm
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing